Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Abstract: Described is a method and an apparatus for producing cured coating films on a substrate surface. Specifically, a portable spraygun may be used to initiate radiation cure without the operative having to be protected from radiation. The spraygun comprises a supply channel for a radiation-curable coating composition, a needle, a reserve for the radiation-curable coating composition, and, optionally, a supply channel for a gas.

Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(?)-menthol.

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.

Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.

Abstract: The present invention relates to a process for edge-halogenation of a graphene material; wherein the graphene material, which is selected from graphene, a graphene nanoribbon, a graphene molecule, or a mixture thereof, is reacted with a halogen-donor compound in the presence of a Lewis acid, so as to obtain an edge-halogenated graphene material.

Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

Abstract: The present invention relates to a process for preparing a graphene nanoribbon, which comprises: (a) providing at least one aromatic monomer compound which is selected from at least one polycyclic aromatic monomer compound, at least one oligo phenylene aromatic monomer compound, or combinations thereof, on a solid substrate, (b) polymerization of the aromatic monomer compound so as to form at least one polymer on the surface of the solid substrate, (c) at least partially cyclodehydrogenating the one or more polymers of step (b), wherein at least step (b) is carried out at a total pressure p(total) of at least 1×10?9 mbar; and a partial oxygen pressure p(O2) and partial water pressure p(H2O) which satisfy the following relation: p(O2)×p(H20)<3×10?14 mbar2.

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.

Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(?)-menthol.

Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.

Abstract: A novel solid form of Voriconazole comprises the active ingredient (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol and fumaric acid. The solid composition comprising the two components shows improved properties such as water solubility, crystallization behavior and stability.

Abstract: The present invention provides photolatent Ti-chelate catalyst compounds of formula (I), wherein R1 is for example C6-C14 aryl which is substituted by one or more R?2, R?3 or R?4; or the two R1 together are unsubstituted linear or branched C1-C12alkylene; R2, R3, R4, R?2, R?3, and R?4 independently of each other are for example hydrogen, halogen or linear or branched C1-C20alkyl; R5, R6 and R7 independently of each other are hydrogen, linear or branched C1-C20alkyl, C6-C14aryl, Br or Cl, provided that not more than one of R5, R6 and R7 is hydrogen; as well as formulations comprising said compounds and defined 1,3-diketones.

Abstract: Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed.

Abstract: A titanium-oxo-chelate catalyst formulation, comprising: (i) at least one compound of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 independently of each other are for example hydrogen, halogen, C1-C20alkyl, C6-C14aryl which is unsubstituted or substituted; or R1, R2 and R3 and/or R4, R5 and R6 and/or R7, R8 and R9 and/or R10, R11 and R12 together with the C-atom to which they are attached each form a C6-C14aryl group which is unsubstituted or substituted; or R1 and R2 and/or R4 and R5 and/or R7 and R8 and/or R10 and R11 together with the C-atom to which they are attached form a 5- to 7-membered carbocyclic ring; at least one chelate ligand compound of the formula (IIa), (IIb) or (IIc), wherein R1, R2, R3, R4, R5 and R6 are defined as above for formula (I), is suitable as photolatent catalyst formulation for polymerizing compounds, which are capable to crosslink in the presence of a Lewis acid.

Abstract: The present invention relates to a method and an apparatus for producing cured coating films on a substrate surface.

Abstract: The present invention relates to polymers comprising a repeating unit of the formula (I), and their use in electronic devices. The polymers according to the invention have excellent 5 solubility in organic solvents and excellent film-forming properties. In addition, high charge carrier mobilities and high temperature stability of the emission color are observed, if the polymers according to the invention are used in polymer light emitting diodes (PLEDs).

Abstract: The present invention provides photolatent Ti-chelate catalyst compounds of formula (I), wherein R1 is for example C6-C14 aryl which is substituted by one or more R?2, R?3 or R?4; or the two R1 together are unsubstituted linear or branched C1-C12alkylene; R2, R3, R4, R?2, R?3, and R?4 independently of each other are for example hydrogen, halogen or linear or branched C1-C20 alkyl; R5, R6 and R7 independently of each other are hydrogen, linear or branched C1-C20 alkyl, C6-C14 aryl, Br or Cl, provided that not more than one of R5, R6 and R7 is hydrogen; as well as formulations comprising said compounds and defined 1,3-diketones.

Abstract: The present invention provides a photolatent Ti-chelate catalyst formulation, comprising (i) at least one compound of the formula (I) wherein R1 is C1-C20alkyl or C2-C20alkyl which is interrupted by one or more non-consecutive O-atoms; Y is formula (II) or optionally substituted phenyl; Y1 is formula (III) or optionally substituted phenyl; Y2 is formula (IV) or optionally substituted phenyl; Y3 is formula (V) or optionally substituted phenyl; R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 independently of each other are hydrogen, halogen, optionally substituted C1-C20alkyl, or R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 independently of each other are optionally substituted C6-C14aryl, provided that only one of R2, R3, R4 is hydrogen and only one of R5, R6, R7 is hydrogen and only one of R8, R9, R10 is hydrogen and only one of R11, R12, R13 is hydrogen; and (ii) at least one chelate ligand compound of the formula IIa, IIb or IIc, wherein Y? is formula (VI) or formula (VII); Y?1 is formula (VI

Abstract: Compounds of the formula I or II wherein R1 is C1-C10haloalkylsulfonyl, halobenzenesulfonyl, C2-C10haloalkanoyl, halobenzoyl; R2 is halogen or C1-C10haloalkyl; Ar1 is phenyl, biphenylyl, fluorenyl, naphthyl, anthracyl, phenanthryl, or heteroaryl, all of which are optionally substituted; Ar?1 is for example phenylene, naphthylene, diphenylene, heteroarylene, oxydiphenylene, phenylene-D-D1-D-phenylene or —Ar?1-A1-Y1-A1-Ar?1—; wherein these radicals optionally are substituted; Ar?1 is phenylene, naphthylene, anthracylene, phenanthrylene, or heteroarylene, all optionally substituted; A1 is for example a direct bond, —O—, —S—, or —NR6—; Y1 inter alia is C1-C18alkylene; X is halogen; D is for example —O—, —S— or —NR6—; D1 inter alia is C1-C18alkylene; are particularly suitable as photolatent acids in ArF resist technology.